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Morgan and Mindoi:10.1016/j.jtcvs.2005.03.017Objective: Advanced age is a major risk factor for ventricular dysfunction and
reduction of cardiac reserve. Finding novel approaches to prevent and attenuate
heart dysfunction associated with advanced age is a major therapeutic challenge.
The present study was designed to test whether engrafted embryonic stem cells
could improve myocardial function in aging hearts.
Methods: Cultured mouse embryonic stem cells used for cell therapy were trans-
fected with green fluorescent protein. Aging rats in the cell-treated group received
intramyocardial injection of embryonic stem cells. Hemodynamic measurement,
myocyte counting, and evaluation of blood flow were performed 6 weeks after cell
transplantation.
Results: Embryonic stem cell therapy partially improved cardiac reserve, as re-
flected by the in vivo response to isoproterenol (INN: isoprenaline) stimulation in
aging hearts 6 weeks after cell implantation. The functional benefits from engrafted
embryonic stem cells were associated with increased myocyte numbers and en-
hanced left ventricular blood perfusion in the aging heart. The characteristic phe-
notype of engrafted embryonic stem cells was identified in the transplanted heart on
the basis of green fluorescent protein–positive spots that were further demonstrated
to differentiate into cardiac tissue with positive staining for cardiac -myosin heavy
chain.
Conclusions: Regenerating cardiomyocytes and increasing regional blood perfusion
in the aging heart after embryonic stem cell transplantation synergistically resulted
in improvement of cardiac function. Embryonic stem cell transplantation might hold
significant clinical potential in attenuating the progressive decrease of cardiac
function associated with advanced aging.
Epidemiologic studies have shown that congestive heart failure is the majorcause of most hospitalizations of persons older than 65 years.1,2 Hearttransplantation is an acceptable alternative for treating end-stage heart failure
in addition to drug treatment; however, only a small number of patients can receive
heart transplantation because of the shortage of donors. Therefore finding novel and
effective approaches to prevent and reduce the pathogenesis of heart dysfunction
associated with advancing age is a major therapeutic challenge.
It has been demonstrated through the last decade that the aging process of the
heart in animals3,4 and human subjects5 is characterized by a significant loss of
cardiac myocytes, especially in the left ventricle. A recent study6 documented that
aging hearts have impaired angiogenic function as a result of decreased production
of a platelet-derived growth factor. Impaired angiogenesis in aging hearts might
facilitate the myocyte loss and subsequently reduce heart function. Recently, ther-
apeutic approaches aimed at promoting angiogenesis and regenerating new cardiac
myocytes have been undergoing intensive investigation. Engrafted cells have been
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the host myocardium7,8 and partially restore the impaired
cardiac function in either cryoinjured9 or infarcted10 hearts.
Our recent studies demonstrated that embryonic stem (ES)
cells can differentiate into cardiac-like cells and improve
cardiac function in postinfarcted rat hearts at 6 weeks11 and
32 weeks12 after cell implantation. The present study was
designed to determine whether ES cells after intramyocar-
dial implantation could regenerate new cardiac myocytes
and enhance cardiac function in aging hearts.
Materials and Methods
ES Cell Preparation and Transplantation
The mouse ES cell line ES-D3 was purchased from the American
Type Culture Collection (ATCC, Manassas, Va) and cultured with
a previously described method.11,12 Before transplantation, cells
dissected from beating clusters were transfected with green fluo-
rescent protein (GFP), a marker for the identification of engrafted
cells. Two days after GFP transfection, cultured ES cells were
trypsinized and resuspended in Joklik modified medium (Sigma,
St Louis, Mo) with a density of 2  107 cells/mL for cell
transplantation.
Experiments were performed in 46 senescent male Fisher 344
rats aged 24 months (obtained from the National Institute on
Aging) and 24 adult male Fisher 344 rats aged 3 months (Charles
River, Wilmington, Mass). The investigation conformed to the
“Guide for the Care and Use of Laboratory Animals” published by
the US National Institutes of Health (National Institutes of Health
publication no. 85-23, revised 1996), and the protocol was ap-
proved by our institutional animal care committee. Animals were
intubated after achievement of anesthesia with pentobarbital (60
mg/kg administered intraperitoneally) and ventilated with room air
by using a small animal ventilator (Harvard Apparatus, South
Natick, Mass). Intramyocardial injection of the ES cell suspension
(50 L, approximately 106 cells) was performed in 3 different sites
(1 in the apex and 2 in the middle of the left ventricle) with a
tuberculin syringe. The adult and aging control rats received the
exact volume of the cell-free medium. Two additional aging rats
receiving stem cell injection were used for monitoring cardiac
arrhythmia. The electrocardiographic (ECG) transmitter (Data Sci-
ences International Inc, St Paul, Minn) was implanted in the rat
abdominal cavity with a previously described method,13 and the
signal was collected by a receiver (Data Sciences International
Inc).
Functional Measurement and -adrenergic
Responsiveness In Vivo
Rats (10 for each group) were anesthetized with pentobarbital (60
mg/kg administered intraperitoneally) at 6 weeks after cell trans-
plantation. Hemodynamic measurements in vivo were performed
with a modified method, as described previously.11,12 After hemo-
dynamic measurements at baseline, serially increasing intravenous
bolus injections of isoproterenol were given in doses of 0.1, 0.3,
1.0, 3.0, and 6.0 g/kg through the femoral vein to determine the
inotropic responsiveness to -adrenergic stimulation. The doses of
isoproterenol used in the present study were chosen on the basis of
a previous report.14 Hemodynamic responses to -adrenergic stim-
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dose-response curve.
Regional Blood Flow Measurement and Numeric
Density of Arterioles
Stable, nonradioactive isotope-labeled microspheres (15 m;
BioPAL Inc, Worcester, Mass) were used to determine the re-
gional blood flow in anesthetized rats 20 minutes after measure-
ment of hemodynamics and -adrenergic stimulation. The method
was modified from a previous publication.15 In brief, a set of
microspheres (1.25  106 in 0.5 mL) was diluted in 0.5 mL of
sanSaline saline (BioPAL Inc) and injected into the left atrium
over 10 seconds during cardiac surgery. Reference blood samples
were withdrawn by using a syringe at a constant rate of 2-minute
intervals through the femoral artery, resulting in a 2-mL sample
used to calculate absolute myocardial blood flow. The rat heart was
then harvested during deep anesthesia. The heart was weighed and
normalized by body weight. The left ventricle was surgically
isolated and cut into transmural slices. Two segments from the
middle of the left ventricle and one from the apex were used for
blood flow measurement. The average myocardial sample weighed
approximately 0.15 g. A piece of the right ventricle was isolated
for tissue control reference. Finally, the tissue and blood samples
were shipped to BioPAL Inc for measurement of active isotope
microspheres and determination of myocardial regional blood
flow.
The numeric density of arterioles (diameter 20 m) was
counted in each area observed (5 for each group) on hematoxylin
and eosin–stained slides by using a light microscope at 400
magnification. Five high-power fields in the transplanted area were
randomly selected; the number of arterioles in each section was
averaged and expressed as the number of arterioles per unit area
(in square millimeters).
Isolated Myocytes and Myocyte Number Counting
In another set of experiments (7 adult control, 6 aging control, and
6 aging rats with cell injection), rats were anesthetized with pen-
tobarbital 6 weeks after cell transplantation. The procedure of
myocyte isolation was modified from a method described previ-
ously.16 Isolated myocytes were counted with a hemocytometer
using a microscope. Hemodynamics were measured as described
above before dissecting cardiomyocytes for linear regression
study.
Identification of Transplanted Cells, Histologic
Analysis, and Western Blotting
Five additional rats for each group were used for histologic study.
The hearts were harvested after achievement of anesthesia and
subsequently dissected into 4 transverse sections from apex to
base. Five-micrometer transverse slices from each section were
prepared for hematoxylin and eosin staining. The survival of
engrafted cells was identified on the basis of GFP-positive clusters
from the aging hearts with stem cell injection. Transformation of
cardiac-like cells from engrafted ES cells was verified by means of
antibody immunostaining for cardiac-specific -myosin heavy
chain (-MHC). Briefly, prepared sections were incubated with a
mouse anti--MHC monoclonal antibody (Berkeley Antibody Co,
Richmond, Calif) for 60 minutes at room temperature. After wash-
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conjugated rhodamine IgG. Immunostaining was performed on
serial sections of the rat heart. Furthermore, the protein levels of
sarcoplasmic reticulum Ca2 ATPase (SERCA2) were measured
in additional left ventricles (5 for each group) with a previously
described method17 to evaluate the activity of cardiac protein.
Statistical Analysis
All data are presented as means SD. Differences between groups
were evaluated by means of 1-way analysis of variance. Means
shown to be different between individual groups were compared
with paired or unpaired Student t tests. The results of isoproterenol
stimulation were analyzed by using 2-way analysis of variance.
Linear regression modeling was used to compare parameters of the
left ventricular systolic pressure (LVSP) and regional blood flow
and parameters of the LVSP and the number of single isolated
myocytes.
Results
General Characteristics and Ventricular Function
After ES Cell Therapy
Three aging control rats with significant weight loss in the
follow-up period before death were excluded. No tumors
were seen during necropsy at the end of the study in any
animals. During the follow-up period, we did not find sig-
nificant cardiac arrhythmias with the telemetric ECG mon-
itoring (data not shown). Our data indicated decrease of
cardiac function in the aging hearts (Table 1) reflected by a
mild reduction of the LVSP, the peak rate of the LVSP
increase (dP/dtmax), and the peak rate of the LVSP de-
crease (dP/dtmax). However, the left ventricular end-
diastolic pressure was significantly increased in aging rats
compared with that seen in adult rats. Six weeks after
TABLE 1. General characteristics of adult rats and aging
rats with or without stem cell therapy
Adult Aging
Aging 
ES cells
BW (g) 352 10 413 15 424 22
HW (g) 0.9 0.1 1.3 0.2 1.2  0.3
HW/BW*100 0.2 0.02 0.3 0.03 0.3  0.04
HR (beats/min) 360 28 372 29 375 26
LVSP (mm Hg) 126 15 108 11 112 10
LVEDP (mm Hg) 5.8 0.7 11.2 1.6† 8.4 1.1*‡
dP/dtmax (mm Hg) 10,296 954 9218 806 9626 915
dP/dtmax (mm Hg) 9329 870 8017 475* 8798 520‡
Values are presented as means  SD. Measurements were conducted at
6 weeks after ES cell or medium injection in 10 rats for each group. BW,
Body weight; HW, heart weight; HW/BW, ratio of heart weight/body
weight; HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, left
ventricular end-diastolic pressure;dP/dtmax, rate of peak left ventricular
systolic pressure increase; dP/dtmax, rate of peak left ventricular sys-
tolic pressure decrease. *P  .05 and †P  .01 versus adult group; ‡P 
.05, aging  ES cell group versus aging group.intramyocardial injection of ES cells, the ventricular func-
The Journal of Thoracition was improved, accompanied by significantly reduced
left ventricular end-diastolic pressure (Table 1). Isoproter-
enol stimulation induced a dose-dependent increase in the
LVSP (Figure 1) in adult control rats, whereas this positive
inotropic effect was markedly blunted in the aging heart. ES
cell transplantation partly restored the inotropic response to
isoproterenol in aging rats 6 weeks after cell injection
(Figure 1).
Left Ventricular Blood Flow and Myocyte
Regeneration After ES Cell Therapy
The regional blood flow measured by using stable, non-
radioactive isotope microspheres was significantly de-
creased in the aging heart without cell treatment (Figure
2, A ) compared with that seen in the adult heart. Cell
transplantation significantly increased the left ventricular
myocardial blood perfusion compared with that seen in
the aging heart without cell injection. Regression analysis
revealed no significant linear relationship (P  .51) be-
tween the LVSP and the left ventricular blood flow
(Figure 2, B ). Additionally, the number of arterioles
increased significantly in the aging heart after ES cell
transplantation compared with that seen in the aging heart
without cell therapy (7.0  1.3 arterioles/mm2 in the
Figure 1. Inotropic response of the LVSP to isoproterenol (ISO)
stimulation during hemodynamic measurements in vivo. Original
representative recordings (A) show the response to isoproterenol
stimulation was blunted in the aging heart without cell treatment.
ES cell transplantation partially restored the inotropic response
to -adrenergic stimulation 6 weeks after cell injection. Summa-
rized data are shown in panel B. *P < .05 and **P < .01 versus
adult group; #P < .05, aging  ES cell group versus aging group.aging plus ES cell group vs 5.2  0.7 arterioles/mm2 in
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the aging group, P  .05), although the arteriolar density
was still lower than that from the adult heart (7.0  1.3
arterioles/mm2 in the aging plus ES cell group vs 10.8 
1.7 arterioles/mm2 in the adult group, P  .05).
The average yields of myocytes in aging left ventricles
without ES cell treatment were significantly lower than
the number of myocytes yielded from adult rat left ven-
tricles (Figure 3, A ). Cell transplantation partially re-
stored the number of myocytes in the aging rat left
ventricles compared with that from aging rat left ventri-
cles without cell therapy. Regression analysis showed
LVSP and myocyte number to have a slightly positive
association, but this did not reach statistical significance
Figure 3. Myocyte counts from the adult and the agin
heart without cell therapy showed significant loss of c
the myocyte number toward normal values. A linear r
between the LVSP and the number of myocytes. LV, Le
< .05, aging  ES cell group versus aging group.
Figure 2. The results of the left ventricular blood flow m
cell transplantation significantly restored the regiona
treatment. A linear regression study (B) demonstrated
blood flow. *P < .05 and **P < .01 versus adult grou(Figure 3, B ).
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Identification of Implanted ES Cells, and Histologic
Study
The protein levels of SERCA2 were analyzed as a ratio
compared with reduced glyceraldehyde-phosphate dehydro-
genase (GAPDH). As shown in Figure 4, there was a
moderate reduction of SERCA2 protein levels in aging left
ventricles compared with that from adult left ventricles. ES
cell treatment resulted in partially restored protein levels of
SERCA2 in left ventricles from aging rats at 6 weeks after
cell injection. Figure 5, A and B, shows engrafted ES cells
distributed within the host myocardium. Those regenerated
tissues were not found in either adult myocardium or the
rt with or without cell transplantation (A). The aging
c myocytes. ES cell transplantation partially restored
ssion study (B) demonstrated a moderate association
ntricle. *P < .05 and **P < .01 versus adult group; #P
rements with isotope microspheres are shown (A). ES
od flow compared with the aging heart without cell
eak association between the LVSP and the regional
< .05, aging  ES cell group versus aging group.g hea
ardia
egre
ft veeasu
l blo
a w
p; #Paging heart without ES cell injection (data not shown).
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fluorescent microscopy in aging myocardium with cell in-
jection. These GFP-positive spots suggest that engrafted ES
cells, or at least some of them, survived in the aging myo-
cardium at 6 weeks after cell injection. There was no
evidence of overt rejection, which is reflected by a lack of
encapsulation and an absence of significant lymphocyte
infiltration. The aging heart with cell transplantation
showed positive staining to cardiac-specific -MHC (Figure
5, D), including the area of newly regenerated cardiac
tissue. Colocalization of engrafted ES cells with fluorescent
staining for -MHC is shown in Fig 5, E. These data
suggest that engrafted ES cells not only survived in the
aging myocardium 6 weeks after cell injection but also
differentiated into cardiac tissue.
Discussion
Advanced aging is associated with a decrease in cardiac
contractility and relaxation.18,19 Potential mechanisms in-
clude a significant loss of cardiac myocytes in animals3 and
in human subjects5 as part of the normal aging process.
Anversa and associates3 reported a significant loss of myo-
cytes in the left ventricles after advanced aging. A further
study by Kajstura and colleagues4 indicated that the pro-
gressive increase in apoptotic and necrotic myocyte death in
the aging hearts of Fisher 344 rats was associated with the
occurrence of ventricular dysfunction, which was apparent
between 16 and 24 months of age.
The results of the present study clearly demonstrate a
significant myocyte loss in aging hearts from Fischer 344
rats at the age of 24 months compared with that seen in the
hearts of 3-month-old rats. ES cell therapy at 6 weeks after
transplantation restored the number of myocytes toward
normal values. The survival of engrafted ES cells was
confirmed by the finding of GFP-positive tissue in the aging
myocardium 6 weeks after cell transplantation, which also
had differentiated into cardiac tissue, as reflected by positive
staining to cardiac-specific -MHC. The positive response
to -adrenergic stimulation was blunted in the aging heart
without ES cell treatment but could be partially restored 6
weeks after ES cell transplantation. This finding is consis-
tent with our previous results with isolated papillary mus-
cles in diseased hearts11,17 and the results of others20 with
perfused aging hearts. The abnormal ventricular function
and isoproterenol responsiveness in the aging heart might be
attributed to the reduction in protein level of SERCA2,
which is mainly responsible for the dysfunction of myocar-
dial performance17 in infarcted rat hearts. Previous studies
showed a reduction in the content and activity of SERCA2
in the aging rat heart21 and senescent human myocardium.22
Loss of cardiomyocytes in the aging rat heart is the major
factor contributing to the reduction of SERCA2 protein
levels. Decrease in the protein levels of SERCA2 in the
The Journal of Thoraciaging heart resulted in impaired intracellular Ca2 handling,
which is responsible for reduction of cardiac performance
and attenuation of the inotropic effect to isoproterenol stim-
ulation. Partial restoration of the inotropic responsiveness to
isoproterenol stimulation by ES cell transplantation was
related to increased protein levels of SERCA2. More ex-
periments are needed to clarify the effects of ES cell therapy
on the expression of major cardiac contraction proteins and
intracellular Ca2 handling in the aging and diseased aging
hearts. In addition, -receptor downregulation might also
evolve into decreased isoproterenol stimulation responsive-
ness in the aging heart that cannot be excluded without
further experimental testing.
Advanced age is accompanied by impaired angiogenesis
in the vascular beds of the heart6,23 and peripheral tissues24
at rest and during ischemic stress. Diminished angiogenesis
in old rats and rabbits was the result of impaired endothelial
function and a lower expression of vascular endothelial
growth factor in nonischemic and ischemic tissue.24 With
the isotope microsphere techniques, the present study dem-
onstrated a significant reduction of the regional blood per-
fusion in the aging left ventricles. ES cell transplantation
partially restored the regional blood flow of the left ventricle
in the aging heart at 6 weeks after cell injection. This finding
Figure 4. Protein expressions of SERCA2 (5 for each group) in
left ventricles from adult rats, aging rats, and aging rats with
cell transplantation determined by means of the Western blot
technique. A, Western blot; B, densitometric analysis of
SERCA2/reduced glyceraldehyde-phosphate dehydrogenase
(GAPDH). *P < .05 and **P < .01 versus adult group; #P < .05,
aging  ES cell group versus aging group.is consistent with our previous reports that showed stem cell
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neovascularization in postinfarcted rat myocardium12 and
increasing the left ventricular blood flow in postinfarcted
porcine hearts.15 New blood supply to the aging myocar-
dium combined synergistically with regenerating cardiomy-
ocytes derived from engrafted ES cells might prevent and
reduce the pathogenesis of ventricular function associated
with advancing age. It is possible that transplanted ES cells
could release transcription signals (eg, endothelial growth
factor) to stimulate neovascularization in the surrounding
tissue, or a portion of the engrafted ES cells might trans-
differentiate into functional endothelial cells. Further exper-
iments are required to understand the sophisticated mecha-
nisms of blood flow improvement after cell transplantation.
The linear regression analyses in the present study do not
indicate a strong correlation between a single variable (ei-
ther myocyte number or blood flow) and ventricular func-
tion. No single factor fully contributes all the benefits from
cell transplantation in the aging hearts. Myogenesis and
angiogenesis from engrafted ES cells provide synergistic
effects leading to the improvement of cardiac function.
There are several limitations in the present study. First,
Figure 5. Panel A shows engrafted ES cells with hemat
after cell transplantation. Panel B shows the higher ma
pointed out by a dot-lined rectangle to show regenera
shown within the aging host myocardium in panel C. Th
heart with cell transplantation, as shown in panel D, in
myocardium but also in the regenerated tissue. Panel
fluorescent staining for cardiac -MHC.cardiac function was measured in the unloaded condition.
552 The Journal of Thoracic and Cardiovascular Surgery ● AuguPreload, afterload, and heart rate might affect the functional
difference between the young and aging hearts. Extensive
systematic evaluation of cardiac function under the condi-
tions of different loading conditions should be conducted in
a future study.
Second, linear regression analyses might not reflect the
natural feature of the host hearts after cell transplantation.
The mechanism of cell therapy for cardiac repair is quite
complicated and has not been fully addressed yet. Extensive
explanation from regression analyses should be done cau-
tiously because even a more complete multivariable regres-
sion study might not establish a causal relationship.
Third, myocyte increase after cell transplantation might
not only result from engrafted ES cells per se but also from
decrease of the apoptotic process in the aging myocardium
caused by cardiac-protecting factors that were released from
engrafted ES cells. Augmentation of angiogenesis results in
an increase in left ventricular blood flow that might also
contribute partially to a reduction in the process of apoptosis
in the advanced aging heart.
Fourth, although there was no evidence of ventricular
n and eosin staining in the aging myocardium 6 weeks
cation image corresponding with the image in panel A
issue from implanted ES cells. GFP-positive spots are
MHC staining of the myocardial section from the aging
tes the positive staining not only displayed in the host
ows colocalization of transplanted ES cells by usingoxyli
gnifi
ted t
e -
dica
E sharrhythmia in the aging rat heart after ES cell transplanta-
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should be performed to test cell therapy–associated arrhyth-
mia before using this novel approach clinically in patients.
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